We are live on
!
Find out more
AQR Capital Management Portfolio holdings
AUM
$218B
1-Year Est. Return
29.41%
This Fund
S&P 500
This Quarter
Est. Return
-12.77%
1 Year Est. Return
+29.41%
3 Year Est. Return
+92.15%
5 Year Est. Return
+116.61%
10 Year Est. Return
+435.72%
AUM
$44.2B
AUM Growth
-$8.44B
(-16%)
Cap. Flow
-$301M
Cap. Flow
% of AUM
-0.68%
Top 10 Holdings %
Top 10 Hldgs %
14.01%
Holding
2,360
New
150
Increased
1,005
Reduced
998
Closed
187
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$209M |
| 2 |
CVS Health
CVS
|
+$195M |
| 3 |
Tyson Foods
TSN
|
+$136M |
| 4 |
ExxonMobil
XOM
|
+$135M |
| 5 |
LyondellBasell Industries
LYB
|
+$130M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Thermo Fisher Scientific
TMO
|
+$239M |
| 2 |
Microsoft
MSFT
|
+$204M |
| 3 |
Johnson & Johnson
JNJ
|
+$157M |
| 4 |
Amazon
AMZN
|
+$144M |
| 5 |
Walmart Inc
WMT
|
+$137M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.23% |
| 2 | Healthcare | 16.49% |
| 3 | Financials | 11.74% |
| 4 | Industrials | 11.47% |
| 5 | Consumer Discretionary | 10.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
451
FirstEnergy
FE
$27.1B
| $22.9M | 0.05% |
596,970
+157,156
| +36% | +$6.71M |
|
452
Akamai
AKAM
$16.9B
| $22.9M | 0.05% |
252,853
-6,763
| -3% | -$705K |
|
453
Southern Company
SO
$105B
| $22.8M | 0.05% |
321,540
-125,451
| -28% | -$9.21M |
|
454
Ingredion
INGR
$6.53B
| $22.6M | 0.05% |
256,886
-513
| -0.2% | -$45.9K |
|
455
Manhattan Associates
MANH
$11.4B
| $22.5M | 0.05% |
199,739
-20,874
| -9% | -$2.6M |
|
456
StoneCo
STNE
$2.52B
| $22.4M | 0.05% |
2,958,958
+2,536,873
| +601% | +$24.3M |
|
|
FLG
457
Flagstar Bank National Association
FLG
$5.82B
| $22.3M | 0.05% |
837,439
+314,677
| +60% | +$9.05M |
|
458
Chemed
CHE
$7.18B
| $22.2M | 0.05% |
47,290
-5,168
| -10% | -$2.52M |
|
|
UMPQ
459
DELISTED
Umpqua Holdings Corp
UMPQ
| $22.1M | 0.05% |
1,340,137
+229,506
| +21% | +$3.98M |
|
460
FedEx
FDX
$76.9B
| $22.1M | 0.05% |
97,632
-20,555
| -17% | -$4.39M |
|
|
HZNP
461
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $22M | 0.05% |
275,390
+77,344
| +39% | +$7.32M |
|
462
Booz Allen Hamilton
BAH
$9.37B
| $21.9M | 0.05% |
247,610
-79,583
| -24% | -$6.79M |
|
463
Highwoods Properties
HIW
$3.41B
| $21.8M | 0.05% |
642,729
+211,143
| +49% | +$8.33M |
|
464
Zebra Technologies
ZBRA
$17.9B
| $21.6M | 0.05% |
74,358
-104,290
| -58% | -$36.3M |
|
|
ABMD
465
DELISTED
Abiomed Inc
ABMD
| $21.6M | 0.05% |
87,126
-27,698
| -24% | -$7.47M |
|
466
Copart
CPRT
$27.4B
| $21.6M | 0.05% |
807,376
+167,392
| +26% | +$4.76M |
|
467
Weyerhaeuser
WY
$18.2B
| $21.5M | 0.05% |
649,288
-71,350
| -10% | -$2.72M |
|
468
Belden
BDC
$5.28B
| $21.5M | 0.05% |
411,285
+120,294
| +41% | +$6.44M |
|
469
Trane Technologies
TT
$105B
| $21.5M | 0.05% |
167,205
-251,974
| -60% | -$34.8M |
|
470
Ciena
CIEN
$54.9B
| $21.4M | 0.05% |
477,252
+200,297
| +72% | +$10.4M |
|
471
NetApp
NTAP
$39B
| $21.4M | 0.05% |
329,941
+54,310
| +20% | +$3.91M |
|
472
Cathay General Bancorp
CATY
$4.23B
| $21.3M | 0.05% |
552,226
+84,663
| +18% | +$3.46M |
|
473
Murphy USA
MUSA
$10.2B
| $21M | 0.05% |
90,312
-29,288
| -24% | -$6.9M |
|
474
Loews
L
$23.3B
| $20.9M | 0.05% |
357,280
+249,151
| +230% | +$15.7M |
|
475
Cheniere Energy
LNG
$54.9B
| $20.8M | 0.05% |
156,585
-44,200
| -22% | -$6.02M |
|
Similar funds
VGA
AQR Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, AQR Capital Management held 2,360 positions worth $44.2B, down 16% from $52.7B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
AQR Capital Management's Q2 2022 filing shows 150 new, 1,005 increased, 998 reduced and 187 closed positions. Its largest new stake was Fluor: 339,891 shares worth $7.86M. The largest sale was Thermo Fisher Scientific, an estimated $239M.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 23% a quarter earlier, followed by Healthcare and Financials.
- AQR Capital Management's largest Q2 2022 buy was Fluor: 339,891 shares worth $7.86M.
- AQR Capital Management added most to Gilead Sciences in Q2 2022, an estimated $209M increase.
- AQR Capital Management's biggest Q2 2022 reduction was Thermo Fisher Scientific, cutting an estimated $239M.
- AQR Capital Management fully exited Roku in Q2 2022, selling an estimated $32.5M.
- AQR Capital Management's ten largest holdings make up 14% of its $44.2B portfolio in Q2 2022.
- AQR Capital Management opened 150 new positions and closed 187 in Q2 2022.
- AQR Capital Management's portfolio value fell 16% quarter-over-quarter to $44.2B.
Based on AQR Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.